1. Home
  2. BTOC vs IFRX Comparison

BTOC vs IFRX Comparison

Compare BTOC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTOC

Armlogi Holding Corp. Common Stock

HOLD

Current Price

$0.65

Market Cap

43.6M

Sector

N/A

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.09

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTOC
IFRX
Founded
2020
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.6M
86.0M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
BTOC
IFRX
Price
$0.65
$1.09
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
1.4M
7.7M
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$197,399,541.00
$73,729.00
Revenue This Year
$34.89
N/A
Revenue Next Year
$14.53
$1,075.42
P/E Ratio
N/A
N/A
Revenue Growth
17.35
N/A
52 Week Low
$0.41
$0.71
52 Week High
$6.10
$2.82

Technical Indicators

Market Signals
Indicator
BTOC
IFRX
Relative Strength Index (RSI) 53.44 42.21
Support Level $0.56 $0.92
Resistance Level $0.62 $1.28
Average True Range (ATR) 0.06 0.11
MACD 0.02 -0.02
Stochastic Oscillator 86.29 30.42

Price Performance

Historical Comparison
BTOC
IFRX

About BTOC Armlogi Holding Corp. Common Stock

Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: